Weight-Loss Pill by Wegovy Makers Shows 13% Weight Reduction in Phase 1 Trials
The Efficacy of Amycretin in Weight Loss
Novo Nordisk, the renowned maker of Ozempic and Wegovy, has announced promising results from its early Phase 1 clinical trial of the experimental weight-loss pill, amycretin. After three months, participants experienced an impressive weight reduction of up to 13%. This finding significantly surpasses the approximate 6% weight loss documented by those on Wegovy during a similar timeframe.
Key Findings from the Trial
- Amycretin demonstrated both safety and tolerability, with side effects akin to those expected from other GLP-1 medications.
- Common side effects reported were nausea, vomiting, diarrhea, and constipation.
- The mechanism of action for amycretin includes functioning as both a GLP-1 and amylin receptor agonist, influencing appetite and blood sugar levels.
Amycretin Versus Existing Treatments
The distinct pharmacological mechanism of amycretin, the daily oral dosage, is believed to provide greater appeal compared to Wegovy's weekly injection format.
For more information regarding this promising drug, please visit the source for further details.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.